Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies

This phase I trial tests the safety, side effects and best infusion dose of genetically engineered cells called anti-CD19/CD20/CD22 chimeric antigen receptor (CAR) T-cells following a short course of chemotherapy with cyclophosphamide and fludarabine in treating patients with lymphoid cancers (malignancies) that have come back (recurrent) or do not respond to treatment (refractory). Lymphoid malignancies eligible for this trial are: non-Hodgkin lymphoma (NHL), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), and B-prolymphocytic leukemia (B-PLL). T-cells (a type of white

Trial Details

NCT ID
NCT05418088
Phase
PHASE1
Sponsor
Sumithira Vasu
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • Anti-CD19/CD20/CD22 CAR T-Cells
  • Cyclophosphamide
  • Fludarabine Phosphate
  • Echocardiography
  • Multigated Acquisition Scan
  • Biopsy
Locations (sample)
  • Columbus, Ohio, United States|39.96118,-82.99879
  • Columbus, Ohio, United States|39.96118,-82.99879

Key Eligibility Criteria

  • Adult subjects with relapsed or refractory non-Hodgkin lymphoma with lesions =\< 5 cm, indolent lymphomas, chronic lymphocytic leukemia without Ric…
  • OR adult subjects with lymphoid blast crisis, acute lymphoblastic leukemia, chronic lymphocytic leukemia with Richter's transformation, non-Hodgkin…
  • OR Pediatric subjects with Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma
  • Subjects must have been treated with at least two lines of therapy. Disease must have either progressed after the last regimen or presented failure…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →